# colorectal cancer - gemini-3.6-flash

- Benchmark system: E2seq + Agent RAG
- Repeat: 6
- Task type: PROGNOSIS
- Tissue / sample source: colorectal tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: Google Gemini / gemini-3.6-flash
- Message SHA-256: dfb8fe82357dbea353d34030380d74028b528c91505f5793c7261ee9e4376675
- Response HTTP status: 200
- Prompt tokens: 120650
- Completion tokens: 98825
- Reasoning tokens: 48968
- Total tokens: 219475
- API requests reported: 8
- Elapsed seconds: 145.061
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1848.064
- Question handoff seconds: 1861.273
- Final benchmark system: E2seq; file rank 5/5; original repeat 6; model vendor: Google Gemini

---
### 1. Overall Biological Interpretation

This transcriptomic survival analysis evaluated 100 statistically significant unique genes (54 risk-associated with hazard ratio $\text{HR} > 1$, and 46 protective-associated with $\text{HR} < 1$) derived from colorectal cancer (CRC) primary tumor tissue. Integrating these prognostic features reveals a clear dual biological axis governing overall survival (OS):

1. **Stroma-Invasive and EMT-Driven Risk Program ($\text{HR} > 1$):** High risk is driven by upregulated activators of the extracellular matrix (ECM), epithelial-mesenchymal transition (EMT), non-coding RNA regulatory axes, and immunosuppressive microenvironments. Key drivers include **INHBB** ($\text{HR} = 1.433, P = 1.999 \times 10^{-8}$), **DCBLD2** ($\text{HR} = 1.408, P = 9.860 \times 10^{-7}$), **SCARA3** ($\text{HR} = 1.377, P = 8.905 \times 10^{-8}$), **ZEB1-AS1** ($\text{HR} = 1.372, P = 9.829 \times 10^{-7}$), **TPM4** ($\text{HR} = 1.364, P = 1.304 \times 10^{-6}$), **ITGBL1** ($\text{HR} = 1.299, P = 1.959 \times 10^{-5}$), and ecto-5'-nucleotidase **NT5E** ($\text{HR} = 1.313, P = 4.326 \times 10^{-5}$).
2. **Epithelial Lineage, Metabolic, and Antigen-Presentation Protective Program ($\text{HR} < 1$):** Favorable survival is strongly tied to preserved intestinal cell differentiation, functional mitochondrial oxidative phosphorylation (OXPHOS), central carbon metabolism, and intact antigen loading. Key markers include lineage master regulators **CDX2** ($\text{HR} = 0.748, P = 2.985 \times 10^{-5}$) and **CDX1** ($\text{HR} = 0.781, P = 9.335 \times 10^{-5}$), apical transporter **MYO5B** ($\text{HR} = 0.748, P = 1.607 \times 10^{-5}$), mitochondrial subunits/chaperones **ATP23** ($\text{HR} = 0.688, P = 4.855 \times 10^{-7}$) and **NDUFA9** ($\text{HR} = 0.689, P = 1.107 \times 10^{-6}$), metabolic enzymes **CS** ($\text{HR} = 0.754, P = 3.584 \times 10^{-5}$) and **ACSS2** ($\text{HR} = 0.758, P = 1.035 \times 10^{-4}$), and immune chaperone **TAPBPL** ($\text{HR} = 0.711, P = 4.919 \times 10^{-6}$).

---

### 2. Core Biological Programs

```
                  COLORECTAL CANCER PROGNOSIS AXIS
                  
       RISK-ASSOCIATED (HR > 1)            PROTECTIVE-ASSOCIATED (HR < 1)
  +---------------------------------+  +----------------------------------+
  | Program 1: TGF-β & ECM          |  | Program 2: Intestinal Lineage    |
  | (INHBB, ITGBL1, TPM4, DCBLD2)   |  | (CDX2, CDX1, MYO5B, LGALS4)      |
  +---------------------------------+  +----------------------------------+
  | Program 3: Purinergic / EMT     |  | Program 4: OXPHOS & Metabolism   |
  | (NT5E, ZEB1-AS1, MIR31HG)       |  | (NDUFA9, ATP23, CS, ACSS2)       |
  +---------------------------------+  +----------------------------------+
```

#### Program 1: TGF-β Superfamily and Extracellular Matrix Remodeling
* **Prognostic Association:** Risk-associated ($\text{HR} > 1$, adverse OS).
* **Major Supporting Genes:** `INHBB` ($\text{HR} = 1.433$), `ITGBL1` ($\text{HR} = 1.299$), `DCBLD2` ($\text{HR} = 1.408$), `TPM4` ($\text{HR} = 1.364$), `ADAMTS18` ($\text{HR} = 1.263$), `ABL2` ($\text{HR} = 1.301$).
* **Standardized Pathway:** Reactome *Extracellular Matrix Organization* (R-HSA-1474244) / GO *Extracellular Matrix Structural Constituent* (GO:0005201).
* **Biological Rationale:** `INHBB` encodes the activin $\beta\text{B}$ subunit, a TGF-β family ligand that promotes stromal activation and EMT in CRC. `ITGBL1` (integrin subunit-like) and `TPM4` (tropomyosin 4) modulate cell matrix adhesion and actin cytoskeleton organization, facilitating tumor cell invasion and cancer-associated fibroblast (CAF) alignment.
* **Evidence & Limitations:** High direct statistical significance in the input dataset ($P < 10^{-5}$); supported by literature on CRC stromal invasion (Europe PMC: 41992239). *Limitation:* External statistical validation was not performed on an independent cohort, and bulk tumor expression cannot distinguish malignant cell intrinsic expression from stromal fibroblast abundance.

#### Program 2: Intestinal Epithelial Lineage and Mucosal Differentiation
* **Prognostic Association:** Protective-associated ($\text{HR} < 1$, favorable OS).
* **Major Supporting Genes:** `CDX2` ($\text{HR} = 0.748$), `CDX1` ($\text{HR} = 0.781$), `MYO5B` ($\text{HR} = 0.748$), `LGALS4` ($\text{HR} = 0.771$), `CCL15` ($\text{HR} = 0.753$).
* **Standardized Pathway:** GO *Cell Fate Commitment* (GO:0045165) / Reactome *Intestinal Epithelium Maintenance*.
* **Biological Rationale:** `CDX2` and `CDX1` are intestine-specific caudal-type homeobox transcription factors essential for terminal differentiation of colonic enterocytes. `MYO5B` mediates apical membrane trafficking, and `LGALS4` (Galectin-4) stabilizes epithelial cell-cell contact and mucosal integrity. Their down-regulation marks dedifferentiation and stemness gain.
* **Evidence & Limitations:** Strong published literature (PubMed: 30631044) linking loss of CDX2 to Wnt pathway hyperactivation and poor prognosis in colon cancer. *Limitation:* External statistical validation was not performed.

#### Program 3: Mitochondrial Respiration and Central Carbon Metabolism
* **Prognostic Association:** Protective-associated ($\text{HR} < 1$, favorable OS).
* **Major Supporting Genes:** `NDUFA9` ($\text{HR} = 0.689$), `ATP23` ($\text{HR} = 0.688$), `ATP5G1` ($\text{HR} = 0.747$), `ATP5B` ($\text{HR} = 0.748$), `CS` ($\text{HR} = 0.754$), `ACSS2` ($\text{HR} = 0.758$), `OGDHL` ($\text{HR} = 0.686$), `GLYCTK` ($\text{HR} = 0.709$), `MCCC2` ($\text{HR} = 0.739$).
* **Standardized Pathway:** Reactome *The Citric Acid (TCA) Cycle and Respiratory Electron Transport* (R-HSA-1428517) / KEGG *Glyoxylate and Dicarboxylate Metabolism* (hsa00630).
* **Biological Rationale:** Subunits of mitochondrial Complex I (`NDUFA9`), ATP synthase (`ATP5G1`, `ATP5B`), mitochondrial chaperone (`ATP23`), and TCA cycle enzymes (`CS`, `ACSS2`, `OGDHL`) coordinate oxidative energy generation. High mitochondrial oxidative capacity correlates with well-differentiated, less aggressive tumors.
* **Evidence & Limitations:** Multiple concordant genes in the input dataset ($\text{HR} = 0.685\text{--}0.758$). *Limitation:* External statistical validation was not performed; functional metabolic flux was not experimentally measured in this sample set.

#### Program 4: Immunosuppressive Ecto-Nucleotidase and Non-Coding EMT Axis
* **Prognostic Association:** Risk-associated ($\text{HR} > 1$, adverse OS).
* **Major Supporting Genes:** `NT5E` (CD73, $\text{HR} = 1.313$), `ZEB1-AS1` ($\text{HR} = 1.372$), `MIR31HG` ($\text{HR} = 1.309$), `MSLN` ($\text{HR} = 1.313$), `CYP1B1` ($\text{HR} = 1.285$).
* **Standardized Pathway:** KEGG *Purine Metabolism* (hsa00230) / Hallmark *Epithelial Mesenchymal Transition*.
* **Biological Rationale:** `NT5E` converts extracellular AMP to adenosine, suppressing cytotoxic T-cell and NK-cell anti-tumor activity. Long non-coding RNAs `ZEB1-AS1` and `MIR31HG` act as epigenetic drivers promoting ZEB1-mediated EMT and stemness.
* **Evidence & Limitations:** Supported by clinical literature identifying CD73 as a prognostic biomarker and immunotherapy checkpoint in solid tumors (PubMed: 36480312). *Limitation:* External statistical validation was not performed.

---

### 3. Key Genes and Interaction Modules

| Candidate Gene / Module | Input $\text{HR}$ & Significance | Program Role | Proposed Gene-Gene Relationship Type |
| :--- | :--- | :--- | :--- |
| **INHBB** | $\text{HR} = 1.433$<br>$P = 1.999 \times 10^{-8}$<br>$\text{FDR} = 0.001093$ | Primary driver of TGF-β matrix remodeling | **Regulatory / Pathway co-membership:** Upstream regulator of SMAD phosphorylation and TGF-β downstream target genes. |
| **CDX2** | $\text{HR} = 0.7478$<br>$P = 2.985 \times 10^{-5}$<br>$\text{FDR} = 0.035502$ | Intestinal epithelial lineage commitment | **Regulatory interaction:** Direct transcription factor binding to downstream mucosal differentiation genes (`CDX1`, `LGALS4`, `MYO5B`). |
| **DCBLD2** | $\text{HR} = 1.408$<br>$P = 9.860 \times 10^{-7}$<br>$\text{FDR} = 0.008647$ | Receptor tyrosine kinase signaling & adhesion | **Co-expression / Indirect relationship:** Co-expressed with integrin signal transducer `ABL2` ($\text{HR} = 1.301$). *Note: probe-level direction conflict in underlying platform dataset requires isoform resolution.* |
| **NDUFA9 & ATP23** | NDUFA9: $\text{HR} = 0.6886, P = 1.107 \times 10^{-6}$<br>ATP23: $\text{HR} = 0.6885, P = 4.855 \times 10^{-7}$ | Mitochondrial OXPHOS maintenance | **Pathway co-membership / Physical complex constituent:** `NDUFA9` is a physical subunit of Complex I; `ATP23` is a functional chaperone for ATP synthase. |
| **ZEB1-AS1 & MIR31HG** | ZEB1-AS1: $\text{HR} = 1.372, P = 9.829 \times 10^{-7}$<br>MIR31HG: $\text{HR} = 1.309, P = 4.208 \times 10^{-7}$ | Epigenetic lncRNA regulators of EMT | **Regulatory interaction:** `ZEB1-AS1` epigenetically activates `ZEB1` transcription; `MIR31HG` modulates microRNA processing pathways. |
| **TPM4 & ITGBL1** | TPM4: $\text{HR} = 1.364, P = 1.304 \times 10^{-6}$<br>ITGBL1: $\text{HR} = 1.299, P = 1.959 \times 10^{-5}$ | Cytoskeletal assembly and cell-matrix tension | **Direct physical interaction (TPM4 to actin); Co-expression (ITGBL1):** `TPM4` physically binds actin filaments; `ITGBL1` is co-expressed in CAF-dense stroma. |
| **TAPBPL** | $\text{HR} = 0.7110$<br>$P = 4.919 \times 10^{-6}$<br>$\text{FDR} = 0.019210$ | MHC Class I antigen loading machinery | **Direct physical interaction:** TAPBP-like protein interacts with TAP complex and MHC Class I heavy chains in the endoplasmic reticulum. |
| **NT5E (CD73)** | $\text{HR} = 1.3130$<br>$P = 4.326 \times 10^{-5}$<br>$\text{FDR} = 0.039391$ | Adenosinergic immune evasion | **Pathway co-membership:** Functional enzyme in the purinergic signaling cascade generating extracellular adenosine. |
| **CS & ACSS2** | CS: $\text{HR} = 0.7545, P = 3.584 \times 10^{-5}$<br>ACSS2: $\text{HR} = 0.7577, P = 1.035 \times 10^{-4}$ | Central metabolic acetyl-CoA flux | **Pathway co-membership & STRING interaction:** `CS` (Citrate Synthase) and `ACSS2` (Acetyl-CoA Synthetase) maintain mitochondrial/cytosolic acetyl-CoA pools. |
| **MSLN** | $\text{HR} = 1.3130$<br>$P = 6.100 \times 10^{-5}$<br>$\text{FDR} = 0.045071$ | Cell-surface adhesion and immunotherapy antigen | **Indirect / Putative relationship:** Cell-surface glycoprotein candidate for targeted immunotherapy (Europe PMC: 42363170). |

---

### 4. Validation Priorities

```
                              VALIDATION PIPELINE
  
  [1. Biomarker Panel]      [2. Cell Deconvolution]     [3. Functional Target]
  CDX2/INHBB/NT5E IHC       Single-cell RNA-seq         NT5E / MSLN Inhibition
         │                           │                            │
         ▼                           ▼                            ▼
  Risk Stratification       Disambiguate Tumor/Stroma    Experimental Validation
```

#### Priority 1: Multi-Gene Prognostic Lineage Biomarker Panel
* **Category:** Biomarker
* **Prioritization Rationale:** Combining intestinal lineage loss (`CDX2`, `MYO5B`) with stromal activation (`INHBB`) provides a orthogonal risk score.
* **Dataset Evidence:** `INHBB` ($\text{HR} = 1.433, P = 1.999 \times 10^{-8}$) and `CDX2` ($\text{HR} = 0.748, P = 2.985 \times 10^{-5}$) represent two of the most significant opposing survival signals.
* **External Evidence:** Extensive clinical literature validates CDX2 immunohistochemistry (IHC) as a colon lineage marker, while INHBB promotes CRC cell proliferation and invasion (Europe PMC: 41992239).
* **Next Step for Validation:** Build a multiplex IHC or RT-qPCR assay in an independent retrospective CRC cohort with annotated OS.
* **Evidence Status:** **Supported hypothesis** *(external statistical validation was not performed on this dataset)*.

#### Priority 2: Tumor Microenvironment Cell-Type Deconvolution
* **Category:** Confounding or composition check
* **Prioritization Rationale:** Transcriptomic survival associations for matrix genes (`ITGBL1`, `TPM4`) and immune markers (`TAPBPL`, `CCL15`) may be confounded by varying proportions of CAFs and tumor-infiltrating lymphocytes (TILs).
* **Dataset Evidence:** Multiple risk genes are canonical CAF markers, whereas protective metabolic genes are epithelial-intrinsic.
* **External Evidence:** Single-cell RNA-seq datasets in CRC show distinct segregation of `ITGBL1` in myofibroblasts and `CDX2`/`CS` in epithelial cells.
* **Next Step for Validation:** Apply computational single-cell deconvolution (e.g., CIBERSORTx) or spatial transcriptomics to distinguish tumor-cell-intrinsic prognosis from cell-fraction effects.
* **Evidence Status:** **Supported hypothesis**.

#### Priority 3: Targeting Ecto-Nucleotidase Adenosinergic Immune Suppression
* **Category:** Therapeutic target
* **Prioritization Rationale:** `NT5E` (CD73) is a cell-surface enzyme amenable to small-molecule inhibitors or monoclonal antibodies.
* **Dataset Evidence:** `NT5E` is significantly associated with adverse OS ($\text{HR} = 1.313, P = 4.326 \times 10^{-5}$).
* **External Evidence:** Anti-CD73 antibodies are currently in clinical trials for solid tumors to restore T-cell activation (PubMed: 36480312).
* **Next Step for Validation:** Evaluate anti-CD73 treatment combined with immune checkpoint blockade in CRC patient-derived organoid-autologous T-cell co-cultures.
* **Evidence Status:** **Exploratory hypothesis** *(drug target presence does not establish therapeutic efficacy in this cohort)*.

#### Priority 4: Re-establishment of Mitochondrial Metabolism vs. Glycolytic Switch
* **Category:** Mechanistic hypothesis
* **Prioritization Rationale:** Coordinated down-regulation of mitochondrial genes (`NDUFA9`, `ATP23`, `CS`, `ACSS2`, `OGDHL`) indicates metabolic reprogramming as a feature of aggressive CRC.
* **Dataset Evidence:** Broad multi-gene protective association across Complex I, Complex V, and the TCA cycle ($\text{HR} = 0.685\text{--}0.758$).
* **External Evidence:** Functional mitochondrial suppression is known to facilitate Warburg metabolic adaptation in advanced malignancies.
* **Next Step for Validation:** Measure oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) in primary CRC organoids stratified by CDX2/NDUFA9 expression.
* **Evidence Status:** **Exploratory hypothesis**.

#### Priority 5: Epigenetic Regulation via Long Non-Coding RNAs (ZEB1-AS1 and MIR31HG)
* **Category:** Interaction / network hypothesis
* **Prioritization Rationale:** Non-coding transcripts `ZEB1-AS1` and `MIR31HG` represent potential upstream drivers of EMT and metastatic competence.
* **Dataset Evidence:** `ZEB1-AS1` ($\text{HR} = 1.372, P = 9.829 \times 10^{-7}$) and `MIR31HG` ($\text{HR} = 1.309, P = 4.208 \times 10^{-7}$) rank among the top 5 most significant risk features.
* **External Evidence:** `MIR31HG` and `ZEB1-AS1` have been reported to recruit chromatin remodeling complexes to suppress epithelial genes (PubMed: 34342374).
* **Next Step for Validation:** Perform antisense oligonucleotide (ASO) knockdown of `ZEB1-AS1` in invasive CRC cell lines followed by RNA-seq and transwell invasion assays.
* **Evidence Status:** **Exploratory hypothesis**.

---

### 5. Evidence Grounding

The biological conclusions presented in this report are grounded across structured evidence categories as summarized below:

* **Direct Input Statistics:** Primary statistical values originate exclusively from the user-provided transcriptomic cohort (100 genes, Cox proportional hazards model for OS). *Crucial Caveat:* External statistical validation was not performed, as no independent validation dataset statistics were provided.
* **Pathway & Ontology Evidence:** Standardized annotations from Reactome (e.g., *Extracellular Matrix Organization*, *TCA Cycle*) and QuickGO/KEGG provide functional grouping. These annotations contextualize biological plausibility but do not constitute independent cohort replication.
* **Protein & Regulatory Interaction Evidence:** Interactivity between metabolic enzymes (`CS`, `ACSS2`) and stromal factors (`TPM4`, actin) is anchored by STRING database records. Physical interactions are distinguished from regulatory co-membership.
* **Disease & Clinical Associations:** Clinical relevance is anchored in published literature indexed in PubMed and Europe PMC (e.g., `INHBB` driving CRC malignant phenotypes, PMID: 41992239; `CDX2` suppressing Wnt signaling, PMID: 30631044).
* **Source Independence vs. Overlap:** Literature records from PubMed and Europe PMC share underlying publication indexing. Similarly, Reactome and GO share underlying curate primary literature; these annotations are complementary rather than independent statistical replications.
* **Data Discrepancy & Insufficient Evidence Warning:**
  * *Probe Direction Conflicts:* Underlying platform features for `DCBLD2`, `LOC101928747`, and `BCL2L14` exhibited internal probe-level direction heterogeneity in the full dataset ledger. While primary display probes demonstrate high significance, transcript isoform resolution is required before declaring a single gene-level conclusion.
  * *Causality:* The current observational transcriptomic survival associations are insufficient evidence to establish direct causality for any single candidate gene without experimental perturbation.

---

### 6. Limitations and Alternative Explanations

1. **Tumor Purity and Cell Composition Confounding:** Bulk tissue RNA sequencing reflects a mixture of tumor cells, immune cells, and cancer-associated fibroblasts (CAFs). The elevated risk associated with `ITGBL1`, `TPM4`, and `INHBB` may simply reflect a high stromal fibroblast fraction rather than tumor-cell-intrinsic transcriptional reprogramming.
2. **Absence of Independent External Cohort Validation:** All statistical features derive from a single study cohort. External statistical validation was not performed, making all prognostic hazard ratios exploratory hypotheses until validated in external datasets (such as TCGA-COAD or GEO cohorts).
3. **Unadjusted Clinical Confounders:** Survival hazard ratios were calculated without explicit adjustment for critical clinical variables, including disease stage (TNM), microsatellite instability (MSI/dMMR status), age, surgical resection status, and adjuvant chemotherapy exposure.
4. **Platform Probe Discrepancies and Multi-Gene Loci:** Probe-level mapping for non-coding RNA clusters (e.g., `LOC101928747|RBMX|SNORD61` and `MIR1248|SNORA81|...|EIF4A2`) creates ambiguity regarding which specific RNA transcript drives the observed prognostic signal.
5. **Association vs. Causation Ambiguity:** Correlative survival associations cannot distinguish functional driver genes from bystander transcripts upregulated as a secondary consequence of tumor progression.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=34, external claims checked=0, external mismatches=0, status=needs review.

Answer model API: Google Gemini / gemini-3.6-flash

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 86/100 selected items (records returned); cbioportal 78/100 selected items (records returned); chembl 14/100 selected items (partially returned; some queries failed); civic 7/100 selected items (records returned); clinicaltrials 32/100 selected items (records returned); clinvar 83/100 selected items (records returned); ensembl 41/100 selected items (partially returned; some queries failed); europepmc 866 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 81/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 75/100 selected items (records returned); humanbase 78/100 selected items (records returned); intact 78/100 selected items (records returned); mygene 86/100 selected items (records returned); omnipath 32/100 selected items (records returned); opentargets 40/100 selected items (partially returned; some queries failed); pubmed 699 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 79/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 80/100 selected items (records returned)
Local databases: gutmgene 0/100 selected items (reachable but no records for this batch); hmdb 25/100 selected items (records returned); string 73/100 selected items (records returned); trrust 14/100 selected items (records returned)
